Lapsed Aug 23, 2026 on the fee record · Low confidence
20-year base term ends Dec 16, 2031
First maintenance fee unpaid; grace period ended.
Held by Sunovion Pharmaceuticals Inc.
Filed May 10, 2019 as application 16/409,257 · Granted Aug 23, 2022
Base term, 20 years from filing
Today
Lapsed Aug 23, 2026
2011
2031
Clock starts
Dec 16, 2011
Dec 16, 2011
No longer in force
Aug 23, 2026
Aug 23, 2026
Granted
Aug 23, 2022
Aug 23, 2022
Term would have run to
Dec 16, 2031
Dec 16, 2031
base term
after the term ends
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
Unresolved
Terminal disclaimer
On file, reference document not resolved, so the date above is an upper bound. We do not guess the cap.
0 of 2
Maintenance fees paid
Two maintenance fees can end this term early, the ones due 3.5 and 7.5 years from grant; the third one's grace period runs past the term end. This counts the ones the record shows paid.
7
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
Its term would have run to Dec 16, 2031: its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is on file with no resolved reference, so no cap is applied and none is guessed. Confidence: Low. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Dec 16, 2011, when application PCT/US2011/065665, the earliest non-provisional in its chain, was filed (this one was filed May 10, 2019); a parent in its chain could not be resolved (the next row) | Dec 16, 2031 | High confidence |
| Continuity chain | A parent in the chain could not be resolved | dated from this application's own claim | Medium confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer on file (approved), reference document not resolved | no cap applied, and none guessed | Medium confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 0 of 2 maintenance fees paid | lapsed Aug 23, 2026 | High confidence |
| Computed term end | The steps above, in order | Aug 23, 2026 | Low confidence |
This family
| Application PCT/US2011/065665 | PCT application no patent term | no patent term |
| US 8,414,922 | Lapsed on the fee record Apr 2025 | Apr 2025 |
| US 8,846,074 | Lapsed on the fee record Sep 2026 | Sep 2026 |
| US 9,283,219 | In force no later than Dec 2031 | no later than Dec 2031 |
| US 9,427,412 | Lapsed on the fee record Aug 2024 | Aug 2024 |
| US 10,285,953 | In force no later than Dec 2031 | no later than Dec 2031 |
| US 11,419,769 | this patent Aug 2026 | Aug 2026 |
The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Feb 27, 2020 Reel 51954, frame 610 | Bryson, Nathan John; Giovinazzo, Anthony John | Cynapsus Therapeutics Inc. | Assignment of Assignor's Interest |
| Feb 27, 2020 Reel 51954, frame 724 | Barnhart, Scott David; Koons, Michael Clinton | Arx, LLC | Assignment of Assignor's Interest |
| Feb 27, 2020 Reel 51954, frame 792 | Arx, LLC | Cynapsus Therapeutics Inc. | Assignment of Assignor's Interest |
| Feb 27, 2020 Reel 51955, frame 35 | Sunovion CNS Development Canada ULC | Sunovion Pharmaceuticals Inc. | Assignment of Assignor's Interest |
| Feb 27, 2020 Reel 52045, frame 901 | Cynapsus Therapeutics Inc. | Project Pegasus Sub Acquisition ULC | Assignment of Assignor's Interest |
| Feb 27, 2020 Reel 52885, frame 366 | Project Pegasus Sub Acquisition ULC | Sunovion CNS Development Canada ULC | Merger |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Note
A terminal disclaimer is on file and its reference is not resolved. No cap is applied and none is guessed
Open question
A terminal disclaimer is on file (approved) and its reference document is not resolved. A disclaimer would cap the term earlier than Aug 23, 2026. We will not guess the cap.
Citations
2
later US patents cite this one
That is above the median of utility patents granted in 2022 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.